Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback